Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVX-A12 RSV/hMPV vaccine in older adults
NCT05903183Phase 2Completed
- Sponsor
- Icosavax, Inc.
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of IVX-A12 in respiratory syncytial virus infection (RSV), human metapneumovirus infection (HMPV), sponsored by Icosavax, Inc.. Started May 2023; status: completed.
02
Drugs
IVX-A12
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT05903183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903183.